Video

Bruton Kinase Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma

Author(s):

Kami J. Maddocks, MD,Alexey V. Danilov, MD, PhD

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, discuss the evolution of BTK inhibitors and how they have changed treatment approaches in clinical practice.

Related Videos
1 expert in this video
1 expert in this video
Leo I. Gordon, MD
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
The OncFive: Top Oncology Articles for the Week of 11/17
November 23rd 2024

The OncFive: Top Oncology Articles for the Week of 11/17

Lori A. Leslie, MD
February 27th 2023

FDA Approval Insights: Pirtobrutinib in MCL

Bendamustine/Obinutuzumab Induction in MCL
November 18th 2024

Bendamustine/Obinutuzumab Induction Generates Responses and MRD Negativity in Treatment-Naive MCL

Joshua Brody, MD
December 8th 2022

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

FDA accepts rivoceranib/camrelizumab NDA for HCC, acalabrutinib triplet yields 100% ORR in untreated mantle cell lymphoma, and more from OncLive this week.
October 26th 2024

The OncFive: Top Oncology Articles for the Week of 10/20

Michael Wang, MD
October 22nd 2024

Acalabrutinib Plus Venetoclax/Rituximab Yields 100% ORR in Treatment-Naive Mantle Cell Lymphoma